List of Figures
Figure 1: Cancer Supportive Care Products Market, Global, Revenue Forecast ($m), 2001–2016 15
Figure 2: Cancer Supportive Care, Global, M&A and Licensing Agreements by Geography, 2008–2010 17
Figure 3: Cancer Supportive Care Products Market, Global, Revenue Forecast ($m), 2001–2016 22
Figure 4: Cancer Supportive Care Products Market, Global, Average Annual Cost of Therapy ($), 2001–2016 24
Figure 5: Cancer Supportive Care Products Market, Global, Market Share by Indication (%), 2009 and 2016 26
Figure 6: Cancer Supportive Care Products Market, Geographical Segmentation, Revenue ($m), 2001–2016 28
Figure 7: Cancer Supportive Care Products Market, Market Share by Geography (%), 2009 and 2016 30
Figure 8: Cancer Supportive Care Products Market, Market Share of the Top Five Countries of Europe (%), 2009 and 2016 31
Figure 9: Cancer Supportive Care Products Market, Sales of Generics Versus Branded Drugs ($m), 2001-2016 32
Figure 10: Oral Mucositis and Dry Mouth, World Health Organization Toxicity-based Classification for Oral Mucositis, 2011 43
Figure 11: Oral Mucositis and Dry Mouth, Global, Revenue Forecast ($m), 2001–2016 45
Figure 12: Oral Mucositis and Dry Mouth, Global, Annual Cost of Therapy ($), 2001–2016 47
Figure 13: Oral Mucositis and Dry Mouth, Global, Treatment Usage Pattern (‘000), 2001–2016 49
Figure 14: Oral Mucositis and Dry Mouth, Global, Prevalence Population (‘000), 2001–2016 51
Figure 15: Oral Mucositis and Dry Mouth, Global, Prescription Population (‘000), 2001–2016 52
Figure 16: Oral Mucositis and Dry Mouth, Geographical Segmentation, Revenue ($m), 2001–2016 54
Figure 17: Oral Mucositis and Dry Mouth, Market Share by Geography (%), 2009 and 2016 56
Figure 18: Oral Mucositis and Dry Mouth, Market Share of Top Five Countries of Europe (%), 2009 and 2016 57
Figure 19: Chemotherapy Induced Nausea and Vomiting, Classification and Risk Factors, 2011 58
Figure 20: Chemotherapy Induced Nausea and Vomiting, Global, Revenue Forecast ($m), 2001–2016 60
Figure 21: Chemotherapy Induced Nausea and Vomiting, Global, Annual Cost of Therapy ($), 2001–2016 62
Figure 22: Chemotherapy Induced Nausea and Vomiting, Global, Treatment Usage Pattern (‘000), 2001–2016 64
Figure 23: Chemotherapy Induced Nausea and Vomiting, Global, Prevalence Population (‘000), 2001–2016 66
Figure 24: Chemotherapy Induced Nausea and Vomiting, Global, Prescription Population (‘000), 2001–2016 67
Figure 25: Chemotherapy Induced Nausea and Vomiting, Geographical Segmentation, Revenue ($m), 2001–2016 69
Figure 26: Chemotherapy Induced Nausea and Vomiting, Market Share by Geography (%), 2009 and 2016 71
Figure 27: Chemotherapy Induced Nausea and Vomiting, Market Share of Top Five Countries of Europe (%), 2009 and 2016 72
Figure 28: Cancer Pain, Global, Revenue Forecast ($m), 2001–2016 74
Figure 29: Cancer Pain, Global, Annual Cost of Therapy ($), 2001-2016 76
Figure 30: Cancer Pain, Global, Treatment Usage Patterns (‘000), 2001-2016 78
Figure 31: Cancer Pain, Global, Prevalence Population (‘000), 2001-2016 80
Figure 32: Cancer Pain, Global, Treatment Seeking Population (‘000), 2001-2016 81
Figure 33: Cancer Pain, Global, Diagnosed Population (‘000), 2001-2016 82
Figure 34: Cancer Pain, Global, Prescription Population (‘000), 2001-2016 83
Figure 35: Cancer Pain, Geographical Segmentation, Revenue ($m), 2001–2016 85
Figure 36: Cancer Pain, Market Share by Geography (%), 2009 and 2016 87
Figure 37: Cancer Pain, Market Share of Top Five Countries of Europe (%), 2009 and 2016 88
Figure 38: Chemotherapy Induced Anemia, Global, Revenue Forecast ($m), 2001–2016 90
Figure 39: Chemotherapy Induced Anemia, Global, Annual Cost of Therapy ($), 2001–2016 92
Figure 40: Chemotherapy Induced Anemia, Global, Treatment Usage Pattern (‘000), 2001–2016 94
Figure 41: Chemotherapy Induced Anemia, Global, Prevalence Population (‘000), 2001–2016 96
Figure 42: Chemotherapy Induced Anemia, Global, Prescription Population (‘000), 2001–2016 97
Figure 43: Chemotherapy Induced Anemia, Geographical Segmentation, Revenue ($m), 2001–2016 100
Figure 44: Chemotherapy Induced Anemia, Market Share by Geography (%), 2009 and 2016 102
Figure 45: Chemotherapy Induced Anemia, Market Share of Top Five Countries of Europe (%), 2009 and 2016 103
Figure 46: Chemotherapy Induced Neutropenia, National Cancer Institute’s Common Toxicity Criteria for CINP, 2011 104
Figure 47: Chemotherapy Induced Neutropenia, Global, Revenue Forecast ($m), 2001–2016 106
Figure 48: Chemotherapy Induced Neutropenia, Global, Annual Cost of Therapy ($), 2001–2016 108
Figure 49: Chemotherapy Induced Neutropenia, Global, Treatment Usage Pattern (‘000), 2001–2016 110
Figure 50: Chemotherapy Induced Neutropenia, Global, Prevalence Population (‘000), 2001–2016 112
Figure 51: Chemotherapy Induced Neutropenia, Global, Prescription Population (‘000), 2001–2016 113
Figure 52: Chemotherapy Induced Neutropenia, Geographical Segmentation, Revenue ($m), 2001–2016 115
Figure 53: Chemotherapy Induced Neutropenia, Market Share by Geography (%), 2009 and 2016 117
Figure 54: Chemotherapy Induced Neutropenia, Market Share of Top Five Countries of Europe (%), 2009 and 2016 118
Figure 55: Bone Metastases, Global, Revenue Forecast ($m), 2001–2016 120
Figure 56: Bone Metastases, Global, Annual Cost of Therapy ($), 2001–2016 122
Figure 57: Bone Metastases, Global, Treatment Usage Pattern (‘000), 2001–2016 124
Figure 58: Bone Metastases, Global, Prevalence Population (‘000), 2001–2016 126
Figure 59: Bone Metastases, Global, Prescription Population (‘000), 2001–2016 127
Figure 60: Bone Metastases, Geographical Segmentation, Revenue ($m), 2001–2016 129
Figure 61: Bone Metastases, Market Share by Geography (%), 2009 and 2016 131
Figure 62: Bone Metastases, Market Share of Top Five Countries of Europe (%), 2009 and 2016 132
Figure 63: Cancer Supportive Care Products Market, the US, Revenue Forecast ($m), 2001–2016 133
Figure 64: Cancer Supportive Care Products Market, the US, Average Annual Cost of Therapy ($), 2001–2016 135
Figure 65: Cancer Supportive Care Products Market, the US, Market Share by Indication (%), 2009 and 2016 137
Figure 66: Cancer Supportive Care Products Market, Top Five Countries of Europe, Revenue Forecast ($m), 2001–2016 138
Figure 67: Cancer Supportive Care Products Market, Top Five Countries of Europe, Average Annual Cost of Therapy ($), 2001–2016 140
Figure 68: Cancer Supportive Care Products Market, Top Five Countries of Europe, Market Share by Indication (%), 2009 and 2016 142
Figure 69: Cancer Supportive Care Products Market, Top Five Countries of Europe, Market Share by Country (%), 2009 and 2016 143
Figure 70: Cancer Supportive Care Products Market, Japan, Revenue Forecast ($m), 2001–2016 145
Figure 71: Cancer Supportive Care Products Market, Japan, Average Annual Cost of Therapy ($), 2001–2016 147
Figure 72: Cancer Supportive Care Products Market, Japan, Market Share by Indication (%), 2009 and 2016 149
Figure 73: Cancer Supportive Care Products, Global, Pipeline by Indication, 2010 150
Figure 74: Cancer Supportive Care Products, Global, Pipeline by Phase (%), 2010 151
Figure 75: Oral Mucositis and Dry Mouth, Global, Pipeline by Phase (%), 2010 153
Figure 76: Chemotherapy Induced Nausea and Vomiting, Global, Pipeline by Phase (%), 2010 154
Figure 77: Cancer Pain, Global, Pipeline by Phase (%), 2010 155
Figure 78: Chemotherapy Induced Anemia, Global, Pipeline by Phase (%), 2010 157
Figure 79: Chemotherapy Induced Neutropenia, Global, Pipeline by Phase (%), 2010 158
Figure 80: Bone Metastases, Global, Pipeline by Phase (%), 2010 159
Figure 81: Cancer Supportive Care Products Market, Global, Market Share by Companies (%), 2009 168
Figure 82: Cancer Supportive Care Products Market, Amgen SWOT Analysis, 2011 172
Figure 83: Cancer Supportive Care Products Market, Johnson & Johnson SWOT Analysis, 2011 175
Figure 84: Cancer Supportive Care Products Market, F. Hoffmann-La Roche SWOT Analysis, 2011 177
Figure 85: Cancer Supportive Care Products Market, Novartis SWOT Analysis, 2011 180
Figure 86: Cancer Supportive Care Products Market, Pfizer SWOT Analysis, 2011 183
Figure 87: Cancer Supportive Care Products Market, Global, M&A and Licensing Agreements by Year, 2008–2010 184
Figure 88: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Deal Type, 2008–2010 185
Figure 89: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Indication, 2008–2010 186
Figure 90: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Deal Value, 2008–2010 187
Figure 91: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Geography, 2008–2010 189
Figure 92: GBI Research Market Forecasting Model 199